{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:54:49Z","timestamp":1783738489032,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11926-021-00990-3","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T17:02:52Z","timestamp":1615222972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis"],"prefix":"10.1007","volume":"23","author":[{"given":"Theonymfi","family":"Doudouliaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-5801","authenticated-orcid":false,"given":"Claire T.","family":"Deakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"1","key":"990_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2015","unstructured":"Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015;54(1):50\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"9631","key":"990_CR2","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201\u201312.","journal-title":"Lancet."},{"key":"990_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, et al. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017;84:55\u201364.","journal-title":"J Autoimmun"},{"issue":"2","key":"990_CR4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","volume":"62","author":"AM Huber","year":"2010","unstructured":"Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res. 2010;62(2):219\u201325.","journal-title":"Arthritis Care Res"},{"issue":"10019","key":"990_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671\u20138.","journal-title":"Lancet."},{"issue":"8","key":"990_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"990_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jclinepi.2007.10.024","volume":"61","author":"EM Pullenayegum","year":"2008","unstructured":"\u2022 Pullenayegum EM, Lam C, Manlhiot C, Feldman BM. Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting. J Clin Epidemiol. 2008;61(9):875\u201381 Statistical paper describing the analysis of the efficacy of IVIG and first application of MSM methodology to data on patients with JDM.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"990_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.40418","volume":"70","author":"CT Deakin","year":"2018","unstructured":"\u2022\u2022 Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheum. 2018;70(5):785\u201393 This is a recent study that used a large cohort of JDM patients to assess the efficacy and safety of cyclophosphamide using MSM.","journal-title":"Arthritis Rheum"},{"key":"990_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13063-015-0784-0","volume":"16","author":"LJ McCann","year":"2015","unstructured":"McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli A, et al. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials. 2015;16:268.","journal-title":"Trials."},{"issue":"3","key":"990_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/10543406.2020.1726371","volume":"30","author":"SC Chow","year":"2020","unstructured":"Chow SC, Huang Z. Innovative design and analysis for rare disease drug development. J Biopharm Stat. 2020;30(3):537\u201349.","journal-title":"J Biopharm Stat"},{"key":"990_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.conctc.2017.11.001","volume":"8","author":"K Thorlund","year":"2017","unstructured":"Thorlund K, Golchi S, Mills E. Bayesian adaptive clinical trials of combination treatments. Contemp Clin Trials Commun. 2017;8:227\u201333.","journal-title":"Contemp Clin Trials Commun"},{"issue":"4","key":"990_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ajmg.c.31533","volume":"172","author":"L Abrahamyan","year":"2016","unstructured":"Abrahamyan L, Feldman BM, Tomlinson G, Faughnan ME, Johnson SR, Diamond IR, et al. Alternative designs for clinical trials in rare diseases. Am J Med Genet C: Semin Med Genet. 2016;172(4):313\u201331.","journal-title":"Am J Med Genet C: Semin Med Genet"},{"issue":"4","key":"990_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.1987.03400040111034","volume":"258","author":"CM Roifman","year":"1987","unstructured":"Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA. 1987;258(4):513\u20135.","journal-title":"JAMA."},{"issue":"4","key":"990_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2133.1990.tb01462.x","volume":"123","author":"C Bodemer","year":"1990","unstructured":"Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, de Prost Y. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123(4):545\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"990_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","volume":"91","author":"BA Lang","year":"1991","unstructured":"Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991;91(2):169\u201372.","journal-title":"Am J Med"},{"key":"990_CR16","first-page":"94","volume":"33","author":"KS Barron","year":"1992","unstructured":"Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol Suppl. 1992;33:94\u20137.","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"990_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1365-2133.1994.tb02906.x","volume":"130","author":"E Collet","year":"1994","unstructured":"Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol. 1994;130(2):231\u20134.","journal-title":"Br J Dermatol"},{"issue":"1","key":"990_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/adc.72.1.25","volume":"72","author":"A Sansome","year":"1995","unstructured":"Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. Arch Dis Child. 1995;72(1):25\u20138.","journal-title":"Arch Dis Child"},{"issue":"4","key":"990_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0887-8994(95)00195-6","volume":"13","author":"V Vedanarayanan","year":"1995","unstructured":"Vedanarayanan V, Subramony SH, Ray LI, Evans OB. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol. 1995;13(4):336\u20139.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"990_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/00007611-199508000-00018","volume":"88","author":"C Saadeh","year":"1995","unstructured":"Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J. 1995;88(8):866\u201370.","journal-title":"South Med J"},{"issue":"2","key":"990_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF02230347","volume":"15","author":"M Galeazzi","year":"1996","unstructured":"Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita O, Puddu P. Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol. 1996;15(2):215\u20136.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"990_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/35.10.1029","volume":"35","author":"M Abinun","year":"1996","unstructured":"Abinun M, Estlin E, Gardner-Medwin D, Spickett GP, McNeela BJ, Cant AJ. Failure of first-line therapy with intravenous immunoglobulin in a child with scleromyositis. Br J Rheumatol. 1996;35(10):1029\u201330.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"990_CR23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1442-200x.1999.01132.x","volume":"41","author":"H Kokori","year":"1999","unstructured":"Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S. Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int. 1999;41(6):696\u20137.","journal-title":"Pediatr Int"},{"issue":"10","key":"990_CR24","first-page":"2498","volume":"27","author":"SM Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498\u2013503.","journal-title":"J Rheumatol"},{"issue":"6","key":"990_CR25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/j.1365-2133.2007.07891.x","volume":"156","author":"H Amano","year":"2007","unstructured":"Amano H, Nagai Y, Katada K, Hashimoto C, Ishikawa O. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol. 2007;156(6):1390\u20132.","journal-title":"Br J Dermatol"},{"key":"990_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1756-185X.2008.00336.x","volume":"11","author":"YANGJ-HL Ming-Chun","year":"2008","unstructured":"Ming-Chun YANGJ-HL, Yao-Hsu YANG, Bor-Luen CHIANG. Improvement of juvenile dermatomyositis with calcinosis universalis after treatment with intravenous immunoglobulin. Int J Rheum Dis. 2008;11:77\u201380.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"990_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","volume":"156","author":"DM Levy","year":"2010","unstructured":"Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr. 2010;156(2):302\u20137.","journal-title":"J Pediatr"},{"issue":"12","key":"990_CR28","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1136\/ard.2011.153718","volume":"70","author":"CG Lam","year":"2011","unstructured":"\u2022\u2022 Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089\u201394 Clinical paper describing the analysis of efficacy of IVIG for JDM using MSM.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"990_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jbspin.2012.07.001","volume":"80","author":"M Touimy","year":"2013","unstructured":"Touimy M, Janani S, Rachidi W, Etaouil N, Mkinsi O. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine. 2013;80(1):108\u20139.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"990_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12013-014-9833-7","volume":"69","author":"G Imataka","year":"2014","unstructured":"Imataka G, Arisaka O. Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis. Cell Biochem Biophys. 2014;69(3):747\u20138.","journal-title":"Cell Biochem Biophys"},{"key":"990_CR31","doi-asserted-by":"crossref","unstructured":"Bali S, D'Cruz D, Lazaro M, Inusa BP. Juvenile polymyositis with unremitting pain and progressive loss of motor and bulbar function on a background of sickle cell disease. BMJ Case Rep. 2015;2015.","DOI":"10.1136\/bcr-2014-207579"},{"issue":"1","key":"990_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12969-016-0112-6","volume":"14","author":"F Speth","year":"2016","unstructured":"Speth F, Haas JP, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol Online J. 2016;14(1):52.","journal-title":"Pediatr Rheumatol Online J"},{"key":"990_CR33","doi-asserted-by":"crossref","unstructured":"de Inocencio J, Enriquez-Merayo E, Casado R, Gonzalez-Granado LI. Subcutaneous immunoglobulin in refractory juvenile dermatomyositis. Pediatrics. 2016;137(4).","DOI":"10.1542\/peds.2015-3537"},{"issue":"7","key":"990_CR34","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s10067-019-04576-4","volume":"38","author":"R Haviv","year":"2019","unstructured":"Haviv R, Zehavi T, Pomeranz A, Leibovitch I, Neheman A, Uziel Y. Juvenile polymyositis associated with ureteral necrosis: a diagnostic and therapeutic dilemma-case report and review of the literature. Clin Rheumatol. 2019;38(7):1925\u20139.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"990_CR35","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3899\/jrheum.090953","volume":"37","author":"E Stringer","year":"2010","unstructured":"Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953\u201361.","journal-title":"J Rheumatol"},{"issue":"1","key":"990_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3899\/jrheum.160688","volume":"44","author":"AM Huber","year":"2017","unstructured":"\u2022 Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44(1):110\u20136 This article presents clinical treatment plans for the management of persistent skin rash in JDM. The first of these plans suggests the use of IVIG.","journal-title":"J Rheumatol"},{"issue":"2","key":"990_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"\u2022 Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340 This article presents the SHARE guidelines for the management of JDM. The use of IVIGis suggested for severe or refractory disease.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"990_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.arcped.2018.12.002","volume":"26","author":"B Bader-Meunier","year":"2019","unstructured":"Bader-Meunier B, Gitiaux C, Belot A, Brochard K, Mouy R, Ponce D, et al. French expert opinion for the management of juvenile dermatomyositis. Arch Pediatr. 2019;26(2):120\u20135.","journal-title":"Arch Pediatr"},{"issue":"3","key":"990_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11926-011-0171-0","volume":"13","author":"A Quick","year":"2011","unstructured":"Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13(3):192\u20138.","journal-title":"Curr Rheumatol Rep"},{"issue":"2 Pt 2","key":"990_CR40","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/0090-1229(89)90072-X","volume":"53","author":"UE Nydegger","year":"1989","unstructured":"Nydegger UE, Sultan Y, Kazatchkine MD. The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol. 1989;53(2 Pt 2):S72\u201382.","journal-title":"Clin Immunol Immunopathol"},{"issue":"5","key":"990_CR41","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1172\/JCI110158","volume":"67","author":"NI Abdou","year":"1981","unstructured":"Abdou NI, Wall H, Lindsley HB, Halsey JF, Suzuki T. Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest. 1981;67(5):1297\u2013304.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"990_CR42","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1007\/s10875-010-9394-5","volume":"30","author":"MS Maddur","year":"2010","unstructured":"Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010;30(Suppl 1):S4\u20138.","journal-title":"J Clin Immunol"},{"issue":"27","key":"990_CR43","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000.","journal-title":"N Engl J Med"},{"issue":"Pt 8","key":"990_CR44","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"R Raju","year":"2005","unstructured":"Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005;128(Pt 8):1887\u201396.","journal-title":"Brain."},{"issue":"2","key":"990_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"K Amemiya","year":"2000","unstructured":"Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94(2):99\u2013104.","journal-title":"Clin Immunol"},{"issue":"4","key":"990_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1172\/JCI109915","volume":"66","author":"RJ Kurlander","year":"1980","unstructured":"Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest. 1980;66(4):773\u201381.","journal-title":"J Clin Invest"},{"issue":"5503","key":"990_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484\u20136.","journal-title":"Science."},{"issue":"4","key":"990_CR48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000093870","volume":"55","author":"S Hurnaus","year":"2006","unstructured":"Hurnaus S, Mueller-Felber W, Pongratz D, Schoser BG. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur Neurol. 2006;55(4):204\u20138.","journal-title":"Eur Neurol"},{"key":"990_CR49","unstructured":"medicines.org.uk. Cyclophosphamide 500 mg powder for solution for injection or infusion 2017 [updated 26.06.2017."},{"issue":"1","key":"990_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1212\/WNL.23.1.55","volume":"23","author":"DC Haas","year":"1973","unstructured":"Haas DC. Treatment of polymyositis with immunosuppressive drugs. Neurology. 1973;23(1):55\u201362.","journal-title":"Neurology."},{"issue":"3","key":"990_CR51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1212\/WNL.30.3.286","volume":"30","author":"E Niakan","year":"1980","unstructured":"Niakan E, Pitner SE, Whitaker JN, Bertorini TE. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology. 1980;30(3):286\u201391.","journal-title":"Neurology."},{"issue":"8","key":"990_CR52","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/rheumatology\/36.8.912","volume":"36","author":"Y See","year":"1997","unstructured":"See Y, Martin K, Rooney M, Woo P. Severe juvenile dermatomyositis complicated by pancreatitis. Br J Rheumatol. 1997;36(8):912\u20136.","journal-title":"Br J Rheumatol"},{"issue":"11","key":"990_CR53","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/rheumatology\/40.11.1293","volume":"40","author":"AV Ramanan","year":"2001","unstructured":"Ramanan AV, Sawhney S, Murray KJ. Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology (Oxford). 2001;40(11):1293\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"990_CR54","first-page":"2059","volume":"30","author":"EF Elst","year":"2003","unstructured":"Elst EF, Kamphuis SS, Prakken BJ, Wulffraat NM, van der Net J, Peters AC, et al. Case report: severe central nervous system involvement in juvenile dermatomyositis. J Rheumatol. 2003;30(9):2059\u201363.","journal-title":"J Rheumatol"},{"issue":"4","key":"990_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","volume":"43","author":"P Riley","year":"2004","unstructured":"Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"990_CR56","first-page":"927","volume":"35","author":"KA Rouster-Stevens","year":"2008","unstructured":"Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008;35(5):927\u20139.","journal-title":"J Rheumatol"},{"issue":"2","key":"990_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2011.04.009","volume":"45","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Ohta M, Shimizu Y, Hayashi YK, Nishino I. Anti-signal recognition particle myopathy in the first decade of life. Pediatr Neurol. 2011;45(2):114\u20136.","journal-title":"Pediatr Neurol"},{"issue":"10","key":"990_CR58","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.braindev.2012.02.009","volume":"34","author":"T Kawabata","year":"2012","unstructured":"Kawabata T, Komaki H, Saito T, Saito Y, Nakagawa E, Sugai K, et al. A pediatric patient with myopathy associated with antibodies to a signal recognition particle. Brain and Development. 2012;34(10):877\u201380.","journal-title":"Brain and Development"},{"issue":"2","key":"990_CR59","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3109\/s10165-012-0647-4","volume":"23","author":"T Kishi","year":"2013","unstructured":"Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M, et al. Clinical analysis of 50 children with juvenile dermatomyositis. Mod Rheumatol. 2013;23(2):311\u20137.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"990_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/CND.0b013e31828ee913","volume":"14","author":"M Nagappa","year":"2013","unstructured":"Nagappa M, Taly AB, Sinha S, Gayathri N, Bindu PS, Mahadevan A, et al. Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis. 2013;14(4):161\u20138.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"3","key":"990_CR61","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3109\/14397595.2013.852852","volume":"24","author":"M Momomura","year":"2014","unstructured":"Momomura M, Miyamae T, Nozawa T, Kikuchi M, Kizawa T, Imagawa T, et al. Serum levels of anti-SRP54 antibodies reflect disease activity of necrotizing myopathy in a child treated effectively with combinatorial methylprednisolone pulses and plasma exchanges followed by intravenous cyclophosphamide. Mod Rheumatol. 2014;24(3):529\u201331.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"990_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3109\/14397595.2015.1014137","volume":"27","author":"M Hamada","year":"2017","unstructured":"Hamada M, Tanaka I, Sakurai Y, Hosono Y, Mimori T. Juvenile polymyositis associated with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody in a 13-year-old girl. Mod Rheumatol. 2017;27(3):541\u20134.","journal-title":"Mod Rheumatol"},{"key":"990_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-015-0048-2","volume":"13","author":"H Wakiguchi","year":"2015","unstructured":"Wakiguchi H, Hasegawa S, Hirano R, Kaneyasu H, Wakabayashi-Takahara M, Ohga S. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. Pediatr Rheumatol Online J. 2015;13:49.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"990_CR64","first-page":"162","volume":"41","author":"S Almeida","year":"2016","unstructured":"Almeida S, Braga M, Santos MJ. Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. Acta Reumatol Port. 2016;41(2):162\u20134.","journal-title":"Acta Reumatol Port"},{"issue":"1","key":"990_CR65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","volume":"15","author":"EL Binns","year":"2017","unstructured":"Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al. Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15(1):77.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"990_CR66","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00296-019-04495-2","volume":"40","author":"W Day","year":"2020","unstructured":"Day W, Gabriel C, Kelly RE Jr, Magro CM, Williams JV, Werner A, et al. Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review. Rheumatol Int. 2020;40(11):1883\u201390.","journal-title":"Rheumatol Int"},{"issue":"8","key":"990_CR67","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/art.1780380815","volume":"38","author":"CD Radis","year":"1995","unstructured":"Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995;38(8):1120\u20137.","journal-title":"Arthritis Rheum"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-00990-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-00990-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-00990-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T17:05:45Z","timestamp":1724605545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-00990-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-00990-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"20 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal rights and Informed Consent"}}],"article-number":"24"}}